NEWS
  • March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
  • December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
  • January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
  • January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
  • December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
  • April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
  • February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
  • February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
  • December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
S1 Biopharma
  • COMPANY
    • ABOUT US
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • MEDICAL ADVISORY BOARD
  • PIPELINE
    • OREXA
    • LOREXYS
    • S1B-307
    • S1B-3006
  • A New Vision for addressing Sexual Wellness
    • SEXUAL DYSFUNCTION R&D
    • SCIENTIFIC PUBLICATIONS
    • PARTNERING
  • NEWSROOM
    • PRESS RELEASES
    • MEDIA COVERAGE
  • INVESTORS
    • LOGIN
  • CONTACT US

MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder

Pharmaceutical Processing | In Development: HSDD Treatment for Women

PM360 | Will Lorexys Succeed Where Addyi Flopped?

The Scientist | Opinion: Sexual Dysfunction Matters

Financial Times | S1 Biopharma starts trial of female libido drug

Drug Discovery & Development | A Potential Treatment for Hypoactive Sexual Desire Disorder

Start-Up | Profile of S1 Biopharma

BioWorld | S1 Biopharma Aims for Female Viagra for HSDD Sans Hormones

CEOCFO Magazine | Interview with Nick Sitchon, CEO of S1 Biopharma


  • CONTACT US
  • SITE MAP
  • Terms of Use
  • © S1 biopharma Inc.
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com